Obviously, FDA Loves Opdivo: Another Quick Nod
This article was originally published in Scrip
Executive Summary
Richard Pazdur, director of the FDA's Office of Hematology and Oncology Products, obviously is in love with Bristol-Myers Squibb Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) – granting the drug another remarkably fast approval.